Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.

Davies, G J; Kobrin, I; Caspi, A; Reisin, L H; de Albuquerque, D C; Armagnijan, D; Coelho, O R; Schneeweiss, A

Davies, G J; Kobrin, I; Caspi, A; Reisin, L H; de Albuquerque, D C; Armagnijan, D; Coelho, O R; Schneeweiss, A.

Affiliation

Davies GJ; Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Am Heart J ; 134(2 Pt 1): 220-8, 1997 Aug.

Article in En | MEDLINE | ID: mdl-9313601

Subject(s)

Angina Pectoris/drug therapy; Benzimidazoles/therapeutic use; Calcium Channel Blockers/therapeutic use; Diltiazem/therapeutic use; Tetrahydronaphthalenes/therapeutic use; Adult; Aged; Benzimidazoles/adverse effects; Benzimidazoles/pharmacology; Calcium Channel Blockers/adverse effects; Calcium Channel Blockers/pharmacology; Delayed-Action Preparations; Diltiazem/pharmacology; Double-Blind Method; Exercise Test/drug effects; Female; Hemodynamics/drug effects; Humans; Male; Mibefradil; Middle Aged; Nitroglycerin/therapeutic use; Prospective Studies; Tetrahydronaphthalenes/adverse effects; Tetrahydronaphthalenes/pharmacology

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Tetrahydronaphthalenes / Benzimidazoles / Calcium Channel Blockers / Diltiazem / Angina Pectoris Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 1997 Document type: Article

Search on Google

XML

PubMed Links